Pelican Cancer Foundation logo
Donate Now
Pelican Cancer Foundation logo
Search
  • Home
  • About us
    • About us
    • What we do
      • Our achievements
      • The Future
    • Who we are
      • Trustees
      • Our Team
      • Patrons
      • Annual Accounts
    • Partnerships
    • Vacancies
    • News
  • Education
    • Current Courses
      • OReCO
        • OReCO Videos
        • OReCO Partners & Sponsors
        • Pelican OReCO Workshops
      • LARS
      • NETS
      • Bowel Cancer Screening
    • Completed Courses
      • Pelican IMPACT
        • IMPACT – Completion & Evaluation
        • Workshops
        • IMPACT – Online resources
        • IMPACT – Partners and Sponsors
      • SPECC
        • SPECC – Completion & Evaluation
        • Workshops
        • SPECC – Online resources
        • SPECC – Partners and Sponsors
      • LOREC
      • TIPTOP
        • Workshops
        • TIPTOP – Online resources
        • Bob’s story (prostate cancer)
        • Andrew’s story (prostate cancer)
        • Alan’s story (prostate cancer)
        • Raymond’s story (prostate cancer)
    • Films
      • Surgical videos
    • Book a Course
    • Sponsorship
  • Research
    • Current Research
    • Completed Research
      • Bowel cancer research
        • POLARS
        • MERCURY 2 (Low Rectal Cancer Study)
        • Deferral of surgery study
        • TATME
        • IMPRESS
        • TRIGGER
        • Papers of interest
        • Timing of surgery
        • AMSOEC
        • MINSTREL
        • Completed research
          • Perineal wound healing registry
          • Beyond TME
          • Validation of the LARS score
          • MARVEL: Evaluation of EMVI positive rectal cancer
          • FLEX
          • TME Physical Simulation Model
          • Total Mesorectal Excision (TME)
          • MERCURY research programme
      • Liver cancer research
        • Completed research
          • EORTC studies
        • SERENADE
        • Papers of interest
      • Peritoneal malignancy research
        • Colorectal Peritoneal Malignancy Database
        • Pseudomyxoma Pathology Atlas
      • Previous Research Areas
        • Prostate Cancer Research
          • Prostate cancer
          • Focal therapy and HIFU research
          • MRI research for prostate cancer
          • Prostate cancer colloquiums
          • FORECAST
          • Trachtomap
          • Papers of interest
        • Bladder cancer research
          • Bladder cancer
          • Papers of interest
    • Information for research applicants
      • Peer Review Panel Terms of Reference
      • Research Review Panel
      • Research Grant Application Guidance Notes
      • Terms and conditions of grants
      • Animals in medical research
      • Research costs
    • Clinical trials
  • For Patients
    • Patient stories
      • Anthony’s story (bowel cancer)
      • Elena’s story (bowel cancer)
      • Terry’s story (liver cancer)
      • Derrick’s story (liver cancer)
      • Alex’s story (colorectal cancer)
      • Cheryll’s story (rectal cancer)
      • Eileen’s story
      • Richard’s story – irrigation
      • Tom’s story – complete response
      • Advanced metastatic bowel cancer
    • What is an MDT?
      • What an MRI reveals
      • Reporting cancer outcomes
    • Bowel cancer
      • Our bowel cancer team
      • About bowel cancer treatment – TME
      • April – Bowel Cancer Awareness Month
      • Low rectal cancer
      • Complete response to chemoradiotherapy in rectal cancer
      • Frequently asked questions about bowel cancer
      • Irrigation for colostomies
      • A patient’s advice
      • Symptom checker
      • Bowel cancer – useful contacts
    • Liver cancer
      • Our liver cancer team
      • About liver cancer treatment
      • Interventional radiology
      • Liver cancer – frequently asked questions
      • Carcinoid and neuroendocrine tumours
      • Liver cancer – want to read more?
    • Pseudomyxoma peritonei
    • Getting a second opinion
    • Clinical trials
      • Current clinical trials
    • Tell us your story
    • Still got questions about cancer?
    • Links
  • Support us
    • Make a donation
      • Make a donation
      • Shares
      • In memory
    • Fundraise for us
      • Our fundraisers
      • Fundraising ideas
      • Fundraising challenges
      • Fundraising resources
    • Leave a Gift in your Will
    • Become a Corporate Partner
    • Trusts, Foundations & Philanthropy
    • Tell us your story
  • Contact us

Reporting cancer outcomes

Pathologists are core members of the cancer multidisciplinary team (MDT). At a local level, the pathologist’s role is to provide information for the MDT on the results of biopsy and specimens after surgery. Pathologists can report if cancer is present and then whether the cancer has been successfully removed – this can influence the need for adjuvant therapy.

Arguably one of the fastest ways to improve cancer outcomes is to insist on full reporting of all cancer cases – from diagnosis to death, so that we can better understand current trends, successes and challenges. Pelican has worked closely with Professor Phil Quirke from Leeds on a number of projects to develop cancer reporting. Professor Quirke’s objective is to improve outcomes for cancer patients and to focus on areas where we can make the greatest gains in colorectal cancer. To achieve this, he is sometimes provocative in his statements – for example, here in the journal GUT.

It is only by collecting full and up-to-date data for cancer that we can firstly understand the current situation – our benchmark – and then improve on it.

Over the last five years the Royal College of Pathology has carried out extensive audits and updated protocols so that there is consistency on colorectal cancer reporting.

The most recent work undertaken, in conjunction with CRUK and NCIN, showed the 30 day survival after colorectal cancer surgery. Whilst many centres were upset about the results of this paper, it provides transparency, and demanded that all centres look closely at their results and consider if improvements could be made.

Interestingly, one trust stood out with an exceptionally low mortality rate. When closely investigated, the difference that Mike Parker, President of the Association of Coloproctology of Great Britain and Northern Ireland, could identify was that they were ‘optimising every area of standard practice within a mutually supportive team that communicates well’.

Keep in touch

We love to email you about our latest news, campaigns, research and ways you can support us

Sign Up

You can find out more about your rights, how we use your personal information and how
we keep your details safe and secure by reading our Privacy Policy.

© 2025 Pelican Cancer Foundation. All Rights Reserved. Registered Charity Number: 1141911 - Privacy Policy